Linkedin & Twitter

Tuesday, March 22, 2016

GlaxoSmithKline’s CEO Andrew Witty lo leave Drugmaker


GlaxoSmithKline’s chief executive, Sir Andrew Witty, is to leave the drugmaker next March after collecting a £6.7m pay package last year.

GSK said it had started looking for a successor to the 51-year-old, who joined the company in 1985 from university and has been at the helm since 2008.

The company’s annual report (PDF) showed his total pay and shares package rose to £6.66m last year, from £3.9m in 2014. Performance-based pay made up three-quarters of the 2015 remuneration, including an annual bonus of £2.2m, part of which was deferred, and £2.6m from a performance share plan. His salary stayed at just under £1.1m.

Moncef Slaoui, chairman of GSK global vaccines, an important part of the business, was the second-best-paid executive with a total package of £5.2m, up from £3m, while Simon Dingemans, the chief financial officer, saw his increase to £3.2m, from £1.9m.

Witty has come under pressure to hasten GSK’s turnaround following sliding profits in recent years. Last month, he fended off calls for a break up of the pharmaceuticals, vaccines and toothpaste multinational. He reiterated on Thursday that the company would return to core earnings growth this year, following a 15% decline last year.

Richard Parkes, an analyst at Deutsche Bank, said: “The decision will allow him to step aside at a high point following the company’s expected return to double digit earnings growth in 2016. We continue to be confident the company will meet or exceed these near-term targets driven by delivery on acquisition synergies and strong performance of its HIV business.”

He said Witty’s departure raised two main questions, regarding the dividend and a potential spinout of the consumer division.

“As a reminder GSK has committed to maintaining its dividend out to 2017 and any change to this seems highly unlikely. However, longer term we see it as possible that a new CEO prioritises M&A [mergers and acquisitions] to bolster its pharma business putting the dividend at risk longer term. While this could be funded by a sale or spin out of consumer, we view this as unlikely as it would leave any new CEO more exposed to the pharma division’s weak pipeline unless a transformational deal was tied to this.”

Witty’s reputation was damaged by a corruption scandal in China, which resulted in a £300m fine. He took action to clean up the company’s act. GSK became the first drugmaker to stop payments to doctors to speak on its behalf and to scrap bonus payments tied to prescriptions.

Another bribery scandal in the US, dating back to 2000, led to a record $3bn (£2.1bn) fine for GSK in 2012. Just last month it was accused of cheating the NHS and fined £37.6m over the cost of anti-depressants, but GSK disputed the ruling and said it actually saved the taxpayer money.

However, Witty will also be remembered for the three-part, $20bn deal with Swiss rival Novartis in 2014 to pool consumer healthcare assets and exchange their oncology and vaccine businesses, which was hailed as an innovative deal in the industry.

He said: “By next year, I will have been CEO for nearly 10 years and I believe this will be the right time for a new leader to take over. In making this decision it has been important to me that the board have the time to conduct a full and proper process and that we sustain the momentum of our current business performance.”

GSK’s chairman, Sir Philip Hampton, paid tribute to him, saying: “Andrew’s retirement next year will represent the culmination of 32 years of service and leadership to GSK and the industry.”
Fuente: The Guardian
Haciendo click en cada uno de los links siguientes, Contenidos de nuestros 
TALLERES DE CAPACITACIÓN IN COMPANY, "A MEDIDA" 
de las necesidades de su Organización,
y aplicados específicamente al SECTOR SALUD Y FARMA:



Consultas al mail: medinacasabella@gmail.com
ó al TE: +5411-3532-0510


.·. Miguel Ángel MEDINA CASABELLA, MSM, MBA, SMHS .·.
Especialista en Management Estratégico, Gestión del Cambio e Inversiones
Representante de The George Washington University en Foros y Ferias de LatAm desde 2001
Representante de The George Washington University Medical Center para los Países de LatAm desde 1996
Ex Director Académico y Profesor de Gestión del Cambio del HSML Program para LatAm en GWU School of Medicine & Health Sciences (Washington DC)
CEO, MANAGEMENT SOLUTIONS GROUP LatAm
EMail: medinacasabella@gmail.com
TE Oficina: ( 0054) 11 - 3532 - 0510
TE Móvil (Local): ( 011 ) 15 - 4420 - 5103
TE Móvil (Int´l): ( 0054) 911 - 4420 - 5103
Skype: medinacasabella


MANAGEMENT SOLUTIONS GROUP LatAm ©
(medinacasabella@gmail.com; +5411-3532-0510)
es una Consultora Interdisciplinaria cuya Misión es proveer
soluciones integrales, eficientes y operativas en todas las áreas vinculadas a:

Estrategias Multiculturales y Transculturales, Organizacionales y Competitivas,
Management Estratégico,
Gestión del Cambio,
Marketing Estratégico,
Inversiones,
Gestión Educativa,
Capacitación

de Latino América (LatAm), para los Sectores:

a) Salud, Farma y Biotech,
b) Industria y Servicios,
c) Universidades y Centros de Capacitación,
d) Gobierno y ONGs.
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)